Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Prothena Corporation plc PRTA

Healthcare Biotechnology
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the... see more

Recent & Breaking News (NDAQ:PRTA)

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 2, 2022

Prothena to Report Second Quarter 2022 Financial Results on August 8th

GlobeNewswire August 1, 2022

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 1, 2022

Prothena to Participate in Jefferies Healthcare Conference

GlobeNewswire June 2, 2022

Prothena Reports First Quarter 2022 Financial Results and Business Highlights

GlobeNewswire May 5, 2022

Prothena to Report First Quarter 2022 Financial Results on May 5th

GlobeNewswire April 28, 2022

Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer's Disease

GlobeNewswire April 26, 2022

Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer's Disease

GlobeNewswire March 28, 2022

Prothena to Participate in Stifel 2022 Virtual CNS Days

GlobeNewswire March 21, 2022

Prothena Presents New Data for Alzheimer's and Parkinson's Disease Programs at AD/PD 2022

GlobeNewswire March 16, 2022

Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights

GlobeNewswire February 17, 2022

Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022

GlobeNewswire February 10, 2022

Prothena to Participate in JMP Securities Hematology and Oncology Summit

GlobeNewswire November 29, 2021

Prothena Reports Third Quarter 2021 Financial Results and Business Highlights

GlobeNewswire November 4, 2021

Prothena to Report Third Quarter 2021 Financial Results on November 4th

GlobeNewswire October 28, 2021

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 1, 2021

Prothena Announces Executive Appointments

GlobeNewswire October 1, 2021

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 3, 2021

Prothena to Participate in Upcoming September Healthcare Conferences

GlobeNewswire September 1, 2021

Prothena Reports Second Quarter 2021 Financial Results and Business Highlights

GlobeNewswire August 5, 2021